<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency</span>
        </nav>

        <header class="page-header">
            <h1>Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0012173" target="_blank">
                        MONDO:0012173
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Fatty Acid Oxidation Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) is an autosomal recessive disorder of mitochondrial long-chain fatty acid beta-oxidation caused by biallelic pathogenic variants in HADHA, most commonly the c.1528G&gt;C (p.Glu510Gln) founder mutation. LCHADD selectively impairs the LCHAD catalytic activity within the mitochondrial trifunctional protein (MTP/TFP), leading to energy failure during fasting or physiologic stress and accumulation of toxic long-chain 3-hydroxyacyl intermediates. Clinical manifestations include hypoketotic hypoglycemia, cardiomyopathy, rhabdomyolysis, hepatopathy, peripheral neuropathy, and a distinctive progressive chorioretinopathy not seen in other fatty acid oxidation disorders. Despite improved neonatal survival through newborn screening, long-term morbidity remains substantial, with myopathy in 82%, metabolic decompensations in 80%, and cardiomyopathy in 28% of screened individuals.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">12</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">HADHA molecular function deficiency within mitochondrial trifunctional protein</div>
                
                <div class="item-desc">Biallelic pathogenic variants in HADHA reduce long-chain 3-hydroxyacyl-CoA dehydrogenase catalytic activity within mitochondrial trifunctional protein.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        HADHA
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        catalytic activity
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0003824" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32840329" target="_blank">PMID:32840329</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"LC-FAODs are caused by mutations in nuclear genes encoding mitochondrial enzymes involved in the conversion of dietary long-chain fatty acids (LCFAs) into energy during times of fasting and physiologic stress."</div>
                
                
                <div class="evidence-explanation">Supports molecular dysfunction of mitochondrial FAO enzymes including HADHA in LCHADD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired mitochondrial long-chain fatty acid beta-oxidation</div>
                
                <div class="item-desc">Deficiency of LCHAD catalytic activity blocks the third step of long-chain fatty acid beta-oxidation, reducing acetyl-CoA and reducing equivalent supply for ketogenesis and oxidative phosphorylation. This causes energy failure during fasting, illness, or prolonged exercise when tissues depend on fatty acid oxidation for fuel.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        hepatocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000182" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        cardiac muscle cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        skeletal muscle fiber
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0008002" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        fatty acid beta-oxidation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006635" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        ketone body biosynthetic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0046951" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32840329" target="_blank">PMID:32840329</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"LC-FAODs are caused by mutations in nuclear genes encoding mitochondrial enzymes involved in the conversion of dietary long-chain fatty acids (LCFAs) into energy during times of fasting and physiologic stress."</div>
                
                
                <div class="evidence-explanation">Supports impaired long-chain FAO and stress-related energy failure downstream of HADHA dysfunction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Toxic intermediate accumulation and oxidative stress</div>
                
                <div class="item-desc">Impaired LCHAD activity leads to accumulation of long-chain 3-hydroxyacyl-CoA intermediates and their corresponding acylcarnitines (C16OH, C18OH, C18:1OH). These toxic intermediates induce oxidative stress, lipid peroxidation, and altered cell homeostasis, contributing to tissue damage in heart, skeletal muscle, liver, and retina.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        retinal pigment epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002586" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        lipid oxidation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034440" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrial inner membrane
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005743" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39283617" target="_blank">PMID:39283617</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"When LCHADD-RPE are exposed to docosahexaenoic acid (DHA), they have increased oxidative stress, lipid peroxidation, decreased viability, and are rescued by antioxidant agents potentially explaining the pathologic mechanism of RPE loss in LCHADD."</div>
                
                
                <div class="evidence-explanation">Demonstrates oxidative stress and lipid peroxidation from toxic intermediate accumulation in LCHADD RPE cells.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Cardiolipin remodeling defect and mitochondrial bioenergetic impairment</div>
                
                <div class="item-desc">The TFP alpha-subunit (HADHA) possesses monolysocardiolipin acyltransferase activity linking fatty acid oxidation to cardiolipin remodeling. HADHA mutations disrupt cardiolipin content and composition, leading to reduced mitochondrial maximal respiration and spare respiratory capacity. This secondary mitochondrial membrane defect may underlie stress intolerance and tissue-specific vulnerability.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cardiolipin metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0046473" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        oxidative phosphorylation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006119" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrial inner membrane
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005743" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39088276" target="_blank">PMID:39088276</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CL reduction was universally identified, a simultaneous increase in monolysocardiolipins was discrepant among cells. A similar profile was seen in liver mitochondria isolates from a TFP-deficient mouse model."</div>
                
                
                <div class="evidence-explanation">Demonstrates cardiolipin remodeling defect in TFP/LCHAD-deficient fibroblasts and mouse liver mitochondria.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39088276" target="_blank">PMID:39088276</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"TFP also catalyzes a step in the remodeling of cardiolipin (CL), a phospholipid critical to mitochondrial membrane stability and function."</div>
                
                
                <div class="evidence-explanation">Establishes TFP role in cardiolipin remodeling beyond fatty acid oxidation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">RPE-specific lipid peroxidation and chorioretinopathy</div>
                
                <div class="item-desc">The retinal pigment epithelium (RPE) relies on fatty acid oxidation for energy, and LCHADD causes a tissue-specific block manifesting as progressive chorioretinopathy unique among fatty acid oxidation disorders. RPE cells accumulate 3-hydroxyacylcarnitines and are susceptible to DHA-triggered lipid peroxidation, leading to RPE degeneration and vision loss. Exogenous HADHA gene addition rescues the biochemical and oxidative stress phenotypes.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        retinal pigment epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002586" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        fatty acid beta-oxidation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006635" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        retina
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000966" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39283617" target="_blank">PMID:39283617</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"LCHADD-RPE express TFP subunits and accumulate 3-hydroxy-acylcarnitines, cannot oxidize palmitate, and release fewer ketones than WT-RPE."</div>
                
                
                <div class="evidence-explanation">Demonstrates impaired fatty acid oxidation and metabolite accumulation in LCHADD RPE cells.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38904639" target="_blank">PMID:38904639</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"LCHADD RPE/sclera samples had a 5- to 7-fold increase in long-chain hydroxyacylcarnitines compared to WT, suggesting an impaired LCHAD step in long-chain FAO."</div>
                
                
                <div class="evidence-explanation">Demonstrates tissue-specific accumulation of toxic intermediates in RPE in vivo.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Toxic_intermediate_accumulation_and_oxidative_stress[&#34;Toxic intermediate accumulation and oxidative stress&#34;]
    HADHA_molecular_function_deficiency_within_mitochondrial_trifunctional_protein[&#34;HADHA molecular function deficiency within mitochondrial trifunctional protein&#34;]
    Impaired_mitochondrial_long_chain_fatty_acid_beta_oxidation[&#34;Impaired mitochondrial long-chain fatty acid beta-oxidation&#34;]
    RPE_specific_lipid_peroxidation_and_chorioretinopathy[&#34;RPE-specific lipid peroxidation and chorioretinopathy&#34;]
    Cardiolipin_remodeling_defect_and_mitochondrial_bioenergetic_impairment[&#34;Cardiolipin remodeling defect and mitochondrial bioenergetic impairment&#34;]

    HADHA_molecular_function_deficiency_within_mitochondrial_trifunctional_protein --&gt; Impaired_mitochondrial_long_chain_fatty_acid_beta_oxidation
    Impaired_mitochondrial_long_chain_fatty_acid_beta_oxidation --&gt; Toxic_intermediate_accumulation_and_oxidative_stress
    Impaired_mitochondrial_long_chain_fatty_acid_beta_oxidation --&gt; Cardiolipin_remodeling_defect_and_mitochondrial_bioenergetic_impairment
    Toxic_intermediate_accumulation_and_oxidative_stress --&gt; RPE_specific_lipid_peroxidation_and_chorioretinopathy

    style Toxic_intermediate_accumulation_and_oxidative_stress fill:#dbeafe
    style HADHA_molecular_function_deficiency_within_mitochondrial_trifunctional_protein fill:#dbeafe
    style Impaired_mitochondrial_long_chain_fatty_acid_beta_oxidation fill:#dbeafe
    style RPE_specific_lipid_peroxidation_and_chorioretinopathy fill:#dbeafe
    style Cardiolipin_remodeling_defect_and_mitochondrial_bioenergetic_impairment fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">12</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Digestive<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Eye<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Metabolism<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Musculoskeletal<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Nervous System<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-7">Constitutional<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-8">Other<span class="pill-count">(4)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cardiomyopathy
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001638" target="_blank">
                                Cardiomyopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001638)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38263760" target="_blank">PMID:38263760</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"neonatal decompensations (28%), symptomatic disease course (94%), later metabolic decompensations (80%), cardiomyopathy (28%), myopathy (82%)"</div>
                
                
                <div class="evidence-explanation">Quantifies cardiomyopathy at 28% in the German NBS cohort, supporting OCCASIONAL frequency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37644104" target="_blank">PMID:37644104</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"LCHADD mice exhibit lower ketones with fasting, exhaust earlier during treadmill exercise and develop a dilated cardiomyopathy compared to WT mice."</div>
                
                
                <div class="evidence-explanation">Recapitulates dilated cardiomyopathy in the knock-in mouse model.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hepatopathy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001397" target="_blank">
                                Hepatic steatosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001397)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and hypocarnitinemia."</div>
                
                
                <div class="evidence-explanation">Confirms hepatic steatosis as a presenting feature.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Eye
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Myopia
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000545" target="_blank">
                                Myopia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000545)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38595698" target="_blank">PMID:38595698</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The main ophthalmic symptoms of LCHAD deficiency were choroidal atrophy, disorganization of the outer retinal layer, and myopia."</div>
                
                
                <div class="evidence-explanation">Confirms myopia as part of the ophthalmic phenotype in LCHADD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Metabolism
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypoketotic hypoglycemia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001985" target="_blank">
                                Hypoketotic hypoglycemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001985)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and hypocarnitinemia."</div>
                
                
                <div class="evidence-explanation">Directly supports hypoketotic hypoglycemia as a presenting feature of LCHADD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37644104" target="_blank">PMID:37644104</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"LCHADD mice exhibit lower ketones with fasting, exhaust earlier during treadmill exercise and develop a dilated cardiomyopathy compared to WT mice."</div>
                
                
                <div class="evidence-explanation">Confirms hypoketotic state during fasting in the LCHADD mouse model.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Myopathy
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003198" target="_blank">
                                Myopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003198)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38263760" target="_blank">PMID:38263760</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"neonatal decompensations (28%), symptomatic disease course (94%), later metabolic decompensations (80%), cardiomyopathy (28%), myopathy (82%)"</div>
                
                
                <div class="evidence-explanation">Quantifies myopathy at 82% in the German NBS cohort, the most frequent complication.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Peripheral neuropathy
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0009830" target="_blank">
                                Peripheral neuropathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0009830)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In addition, LCHAD deficiency has specific features, namely peripheral neuropathy and chorioretinopathy."</div>
                
                
                <div class="evidence-explanation">Confirms peripheral neuropathy as a specific feature of LCHADD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Lethargy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001254" target="_blank">
                                Lethargy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001254)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and hypocarnitinemia."</div>
                
                
                <div class="evidence-explanation">Hypoglycemic coma presentation is consistent with severe lethargy during decompensation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-7">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Exercise intolerance
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003546" target="_blank">
                                Exercise intolerance
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003546)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32840329" target="_blank">PMID:32840329</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients may present with rhabdomyolysis induced by exercise; fasting or illness"</div>
                
                
                <div class="evidence-explanation">Supports exercise as a trigger for muscle complications in LC-FAODs including LCHADD, consistent with exercise intolerance.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37644104" target="_blank">PMID:37644104</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"LCHADD mice exhibit lower ketones with fasting, exhaust earlier during treadmill exercise and develop a dilated cardiomyopathy compared to WT mice."</div>
                
                
                <div class="evidence-explanation">Demonstrates exercise intolerance in the LCHADD knock-in mouse model.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-8">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Rhabdomyolysis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003201" target="_blank">
                                Rhabdomyolysis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003201)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other manifestations are cardiomyopathy and rhabdomyolysis, which are frequent in defects of long-chain fatty acid oxidation."</div>
                
                
                <div class="evidence-explanation">Confirms rhabdomyolysis as a frequent manifestation in long-chain FAO defects.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32840329" target="_blank">PMID:32840329</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients may present with rhabdomyolysis induced by exercise; fasting or illness"</div>
                
                
                <div class="evidence-explanation">Supports rhabdomyolysis triggered by exercise, fasting, or illness.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chorioretinopathy
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001135" target="_blank">
                                Chorioretinal dystrophy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001135)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38595698" target="_blank">PMID:38595698</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The main ophthalmic symptoms of LCHAD deficiency were choroidal atrophy, disorganization of the outer retinal layer, and myopia."</div>
                
                
                <div class="evidence-explanation">Details the specific ophthalmic features of LCHADD chorioretinopathy including choroidal atrophy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38904639" target="_blank">PMID:38904639</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"LCHADD mice have progressively decreased visual performance and increased RPE degeneration starting at 6 months."</div>
                
                
                <div class="evidence-explanation">Recapitulates progressive chorioretinopathy in the LCHADD mouse model.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Metabolic decompensation
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0004911" target="_blank">
                                Episodic metabolic acidosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0004911)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32840329" target="_blank">PMID:32840329</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Despite newborn screening, current management options leave many patients continuing to experience major clinical events, and mortality rates remain elevated."</div>
                
                
                <div class="evidence-explanation">Supports persistence of metabolic decompensation episodes despite NBS and treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypocarnitinemia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003234" target="_blank">
                                Decreased circulating carnitine concentration
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003234)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and hypocarnitinemia."</div>
                
                
                <div class="evidence-explanation">Directly supports hypocarnitinemia as a presenting feature of LCHADD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HADHA pathogenic variants causing LCHADD
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal recessive</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38263760" target="_blank">PMID:38263760</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Disease courses in screened individuals with LCHAD and MTP deficiency were similar except for neuropathy, occurring earlier in individuals with MTP deficiency (median 3.9 vs. 11.4 years; p = 0.0447)."</div>
                
                
                <div class="evidence-explanation">Distinguishes LCHADD from MTPD clinical course.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39088276" target="_blank">PMID:39088276</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"A single common mutation, HADHA c.1528G&gt;C (p.E510Q), leads to isolated 3-hydroxyacyl-CoA dehydrogenase deficiency."</div>
                
                
                <div class="evidence-explanation">Distinguishes isolated LCHAD from combined TFP deficiency at the genetic level.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Dietary fat restriction with MCT supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Core dietary management involves restriction of long-chain triglycerides (LCT) to approximately 10% of total energy with supplementation of medium-chain triglycerides (MCT) at 10-25% of total energy. Essential fatty acid intake (linoleic and linolenic acid) must be maintained. Avoidance of prolonged fasting is critical.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39203843" target="_blank">PMID:39203843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In long-chain deficits, long-chain triglyceride restriction should be 10% of total energy, with linoleic acid and linolenic acid intake of 3-4% and 0.5-1% (5/1-10/1 ratio), with medium-chain triglyceride supplementation at 10-25% of total energy"</div>
                
                
                <div class="evidence-explanation">Specifies LCT restriction and MCT supplementation targets for long-chain FAO defects.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39203843" target="_blank">PMID:39203843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment of fatty acid oxidation disorders is based on dietary, pharmacological and metabolic decompensation measures. It is essential to provide the patient with sufficient glucose to prevent lipolysis and to avoid the use of fatty acids as fuel as far as possible."</div>
                
                
                <div class="evidence-explanation">Supports dietary management as the foundation of FAOD treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Emergency glucose infusion for acute decompensation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Acute metabolic decompensation requires emergency IV glucose administration (10% dextrose at approximately 8 mg/kg/min) to suppress lipolysis and catabolism. Cessation of protein and fat intake and monitoring of electrolytes and creatine kinase are essential.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32840329" target="_blank">PMID:32840329</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Long-chain fatty acid oxidation disorders (LC-FAODs) are rare, life-threatening, autosomal recessive genetic disorders characterized by acute crises of energy production and chronic energy deficiency."</div>
                
                
                <div class="evidence-explanation">Supports the need for emergency management of acute metabolic crises.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39203843" target="_blank">PMID:39203843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The main measure in emergency hospital treatment is the administration of IV glucose."</div>
                
                
                <div class="evidence-explanation">Directly supports IV glucose as the primary emergency intervention.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Triheptanoin (Dojolvi)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Triheptanoin is an FDA-approved odd-chain triglyceride providing anaplerotic substrate (propionyl-CoA converted to succinyl-CoA) to support TCA cycle intermediate replenishment and energy generation in long-chain fatty acid oxidation disorders. Reported to reduce decompensation frequency and hospitalizations.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32840329" target="_blank">PMID:32840329</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In recent years, the use of medium, odd-chain fatty acids, such as triheptanoin, have been studied as a treatment of LC-FAODs due to its anaplerotic properties."</div>
                
                
                <div class="evidence-explanation">Supports triheptanoin as an anaplerotic therapy for LC-FAODs.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39203843" target="_blank">PMID:39203843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Trihepatnoin is a new therapeutic option with a good safety and efficacy profile."</div>
                
                
                <div class="evidence-explanation">Confirms triheptanoin as a therapeutic option with favorable profile. Note &#34;Trihepatnoin&#34; is a typo in the original publication abstract.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Newborn screening
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000124" target="_blank">
                            MAXO:0000124
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Expanded newborn screening using tandem mass spectrometry acylcarnitine profiling identifies affected infants presymptomatically. Screening detects elevated C16OH, C18OH, and C18:1OH. While NBS improves neonatal survival, it does not reliably prevent long-term morbidity.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38263760" target="_blank">PMID:38263760</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Sixty-seven individuals with LCHAD/MTP deficiency were included in the study, thereof 54 identified by NBS. All screened individuals with LCHAD deficiency survived"</div>
                
                
                <div class="evidence-explanation">Demonstrates improved survival with NBS but persistent morbidity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37754774" target="_blank">PMID:37754774</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The established &#34;HADHA ratio&#34; = (C16OH + C18OH + C18:1OH)/C0 was significantly elevated in all 54 affected individuals in comparison to the control group."</div>
                
                
                <div class="evidence-explanation">Supports acylcarnitine-based NBS biomarkers for LCHADD detection.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Carnitine supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">L-carnitine supplementation to address secondary carnitine deficiency and support excretion of toxic acyl-CoA intermediates as acylcarnitines. Use remains somewhat controversial but commonly employed.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39203843" target="_blank">PMID:39203843</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The use of carnitine remains controversial and new therapeutic options are under investigation."</div>
                
                
                <div class="evidence-explanation">Acknowledges carnitine supplementation while noting it remains controversial.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and hypocarnitinemia."</div>
                
                
                <div class="evidence-explanation">Supports the rationale for carnitine supplementation given hypocarnitinemia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Ophthalmologic monitoring
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001155" target="_blank">
                            MAXO:0001155
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Regular retinal screening for chorioretinopathy is essential for all LCHADD patients, as choroidal atrophy and pigment dispersion are early signs of retinal degeneration. European metabolic centers concur on the importance of retinopathy screening as part of long-term monitoring.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38245779" target="_blank">PMID:38245779</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The centres concurred in many aspects of long-term monitoring of LCFAOD including the frequency of clinical visits, determination of laboratory parameters, cardiac monitoring and retinopathy screening."</div>
                
                
                <div class="evidence-explanation">Confirms retinopathy screening as a consensus monitoring practice.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38595698" target="_blank">PMID:38595698</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Choroidal atrophy and pigment dispersion were consistently the earliest signs of LCHAD-associated chorioretinopathy."</div>
                
                
                <div class="evidence-explanation">Supports the importance of regular ophthalmologic monitoring to detect early signs.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Genetic counseling for affected families including discussion of autosomal recessive inheritance, recurrence risk (25% for carrier parents), carrier testing, and prenatal diagnostic opportunities.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Because of therapeutic and prenatal diagnostic opportunities in LCHAD deficiency, it is important to recognize this severe disorder early in its course."</div>
                
                
                <div class="evidence-explanation">Supports the importance of early diagnosis and prenatal counseling for LCHADD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cardiac monitoring and management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Regular cardiac monitoring with echocardiography is recommended given the 28% prevalence of cardiomyopathy. European metabolic centers include cardiac monitoring as a consensus practice in long-term follow-up of LCFAOD patients.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38245779" target="_blank">PMID:38245779</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The centres concurred in many aspects of long-term monitoring of LCFAOD including the frequency of clinical visits, determination of laboratory parameters, cardiac monitoring and retinopathy screening."</div>
                
                
                <div class="evidence-explanation">Confirms cardiac monitoring as consensus practice in European metabolic centers.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Fasting and catabolic stress</div>
                
                
                <div class="item-desc">Prolonged fasting, febrile illness, and physiologic stress increase reliance on fatty acid oxidation and trigger metabolic decompensation. Fasting avoidance is the cornerstone of preventive management.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32840329" target="_blank">PMID:32840329</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients may present with rhabdomyolysis induced by exercise; fasting or illness; hepatic dysfunction, including severe hypoglycemia and hyperammonemia; and cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Identifies fasting, exercise, and illness as triggers for clinical manifestations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Long-chain 3-hydroxyacylcarnitines (C16OH, C18OH, C18:1OH)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated long-chain 3-hydroxyacylcarnitines are the hallmark diagnostic biomarkers for LCHADD, detectable on newborn screening by tandem mass spectrometry. These reflect the enzymatic block at the LCHAD step and accumulate in blood, tissues, and RPE.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37754774" target="_blank">PMID:37754774</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The established &#34;HADHA ratio&#34; = (C16OH + C18OH + C18:1OH)/C0 was significantly elevated in all 54 affected individuals in comparison to the control group."</div>
                
                
                <div class="evidence-explanation">Quantifies elevation of diagnostic hydroxyacylcarnitines in all affected patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Diagnosis is suggested by 3-hydroxylated acylcarnitine species in blood and the definitive diagnosis can be made by measuring intermediates of fatty acid beta-oxidation in fibroblasts or by detecting disease causing mutations."</div>
                
                
                <div class="evidence-explanation">Supports 3-hydroxyacylcarnitines as diagnostic biomarkers.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    HADHA ratio (C16OH + C18OH + C18:1OH)/C0
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: A novel composite biomarker ratio proposed by Baydakova et al. (2023) that shows high sensitivity and specificity for LCHADD/MTP deficiency. The ratio was elevated in all 54 affected individuals tested and was not elevated in VLCAD deficiency, providing good differential diagnostic utility.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37754774" target="_blank">PMID:37754774</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"As VLCAD-deficient patients did not show increased &#34;HADHA ratio&#34;, the results emphasized the high specificity of this new ratio."</div>
                
                
                <div class="evidence-explanation">Demonstrates specificity of the HADHA ratio for LCHADD vs VLCAD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Free carnitine (C0)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Secondary carnitine depletion due to increased conjugation and urinary excretion of long-chain acylcarnitines.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10229030" target="_blank">PMID:10229030</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and hypocarnitinemia."</div>
                
                
                <div class="evidence-explanation">Directly supports reduced free carnitine in LCHADD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Ketone bodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Inappropriately low ketone body production during fasting, reflecting impaired hepatic ketogenesis from blocked fatty acid oxidation. Also demonstrated in LCHADD RPE cells in vitro.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39283617" target="_blank">PMID:39283617</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"LCHADD-RPE express TFP subunits and accumulate 3-hydroxy-acylcarnitines, cannot oxidize palmitate, and release fewer ketones than WT-RPE."</div>
                
                
                <div class="evidence-explanation">Demonstrates reduced ketone production in LCHADD cells.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37644104" target="_blank">PMID:37644104</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"LCHADD mice exhibit lower ketones with fasting"</div>
                
                
                <div class="evidence-explanation">Confirms hypoketotic phenotype in the LCHADD mouse model.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Cardiolipin
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Cardiolipin reduction in mitochondrial membranes, with concurrent increase in monolysocardiolipins, reflecting impaired cardiolipin remodeling by the TFP alpha-subunit.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39088276" target="_blank">PMID:39088276</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CL reduction was universally identified, a simultaneous increase in monolysocardiolipins was discrepant among cells. A similar profile was seen in liver mitochondria isolates from a TFP-deficient mouse model."</div>
                
                
                <div class="evidence-explanation">Demonstrates universal cardiolipin reduction in TFP-deficient cells and mouse liver.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
category: Mendelian
creation_date: &#39;2025-06-12T20:16:27Z&#39;
updated_date: &#39;2026-02-28T02:10:00Z&#39;
synonyms:
- LCHADD
- LCHAD deficiency
- Isolated LCHAD deficiency
- Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency
description: &#39;Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) is an autosomal recessive disorder of mitochondrial
  long-chain fatty acid beta-oxidation caused by biallelic pathogenic variants in HADHA, most commonly the c.1528G&gt;C (p.Glu510Gln)
  founder mutation. LCHADD selectively impairs the LCHAD catalytic activity within the mitochondrial trifunctional protein
  (MTP/TFP), leading to energy failure during fasting or physiologic stress and accumulation of toxic long-chain 3-hydroxyacyl
  intermediates. Clinical manifestations include hypoketotic hypoglycemia, cardiomyopathy, rhabdomyolysis, hepatopathy, peripheral
  neuropathy, and a distinctive progressive chorioretinopathy not seen in other fatty acid oxidation disorders. Despite improved
  neonatal survival through newborn screening, long-term morbidity remains substantial, with myopathy in 82%, metabolic decompensations
  in 80%, and cardiomyopathy in 28% of screened individuals.

  &#39;
disease_term:
  preferred_term: long chain 3-hydroxyacyl-CoA dehydrogenase deficiency
  term:
    id: MONDO:0012173
    label: long chain 3-hydroxyacyl-CoA dehydrogenase deficiency
parents:
- Fatty Acid Oxidation Disorder
- Inborn Error of Metabolism
prevalence:
- population: Central and Northern European
  percentage: 1 in 118,336 live births (Poland); carrier frequency 1:240 (Finland)
  notes: &#39;LCHADD is rare with birth prevalence varying by population. Predominantly observed in Central and Northern European
    populations due to the founder c.1528G&gt;C mutation.

    &#39;
  evidence:
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Analysis of the frequency of the G1528C mutation in Finland revealed carrier frequency of 1:240.
    explanation: Provides carrier frequency data in Finland.
  - reference: PMID:38595698
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, typically inherited as a recessive trait, is a
      genetic condition predominantly observed in Central and Eastern Europe, with birth prevalence in Poland amounting to
      1/118,336.
    explanation: Provides birth prevalence estimate for Poland.
progression:
- phase: Neonatal/Infantile onset
  notes: &#39;Presents in infancy with acute metabolic decompensation including hypoketotic hypoglycemia, hepatic steatosis, and
    hypocarnitinemia. Neonatal decompensations occur in 28% of screened individuals.

    &#39;
  evidence:
  - reference: PMID:38263760
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: neonatal decompensations (28%), symptomatic disease course (94%)
    explanation: Quantifies early disease onset despite newborn screening.
- phase: Chronic progressive course
  notes: &#39;Despite improved neonatal survival through NBS, 94% of screened individuals develop symptomatic disease. Long-term
    complications include myopathy (82%), metabolic decompensations (80%), cardiomyopathy (28%), hepatopathy (32%), retinopathy
    (17%), and neuropathy (22%). Hospitalization rates up to 2.4 per year. Dietary adherence decreases with age (75% in year
    1 to 12% by age 10).

    &#39;
  evidence:
  - reference: PMID:38263760
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: While NBS and early treatment result in improved (neonatal) survival, they cannot reliably prevent long-term
      morbidity in screened individuals with LCHAD/MTP deficiency, highlighting the urgent need of better therapeutic strategies
      and the development of disease course-altering treatment.
    explanation: Confirms persistent long-term morbidity despite NBS.
pathophysiology:
- name: HADHA molecular function deficiency within mitochondrial trifunctional protein
  description: &#39;Biallelic pathogenic variants in HADHA reduce long-chain 3-hydroxyacyl-CoA
    dehydrogenase catalytic activity within mitochondrial trifunctional protein.

    &#39;
  genes:
  - preferred_term: HADHA
  biological_processes:
  - preferred_term: catalytic activity
    term:
      id: GO:0003824
      label: catalytic activity
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:32840329
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: LC-FAODs are caused by mutations in nuclear genes encoding mitochondrial enzymes involved in the conversion of dietary long-chain fatty acids (LCFAs) into energy during times of fasting and physiologic stress.
    explanation: Supports molecular dysfunction of mitochondrial FAO enzymes including HADHA in LCHADD.
  downstream:
  - target: Impaired mitochondrial long-chain fatty acid beta-oxidation
    description: Reduced HADHA catalytic activity blocks the LCHAD step of long-chain FAO.
- name: Impaired mitochondrial long-chain fatty acid beta-oxidation
  description: &#39;Deficiency of LCHAD catalytic activity blocks the third step of long-chain
    fatty acid beta-oxidation, reducing acetyl-CoA and reducing equivalent supply
    for ketogenesis and oxidative phosphorylation. This causes energy failure
    during fasting, illness, or prolonged exercise when tissues depend on fatty
    acid oxidation for fuel.

    &#39;
  biological_processes:
  - preferred_term: fatty acid beta-oxidation
    term:
      id: GO:0006635
      label: fatty acid beta-oxidation
  - preferred_term: ketone body biosynthetic process
    term:
      id: GO:0046951
      label: ketone body biosynthetic process
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:32840329
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: LC-FAODs are caused by mutations in nuclear genes encoding mitochondrial enzymes involved in the conversion of dietary long-chain fatty acids (LCFAs) into energy during times of fasting and physiologic stress.
    explanation: Supports impaired long-chain FAO and stress-related energy failure downstream of HADHA dysfunction.
  downstream:
  - target: Toxic intermediate accumulation and oxidative stress
  - target: Cardiolipin remodeling defect and mitochondrial bioenergetic impairment
- name: Toxic intermediate accumulation and oxidative stress
  description: &#39;Impaired LCHAD activity leads to accumulation of long-chain 3-hydroxyacyl-CoA intermediates and their corresponding
    acylcarnitines (C16OH, C18OH, C18:1OH). These toxic intermediates induce oxidative stress, lipid peroxidation, and altered
    cell homeostasis, contributing to tissue damage in heart, skeletal muscle, liver, and retina.

    &#39;
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: lipid oxidation
    term:
      id: GO:0034440
      label: lipid oxidation
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  locations:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  evidence:
  - reference: PMID:39283617
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: When LCHADD-RPE are exposed to docosahexaenoic acid (DHA), they have increased oxidative stress, lipid peroxidation,
      decreased viability, and are rescued by antioxidant agents potentially explaining the pathologic mechanism of RPE loss
      in LCHADD.
    explanation: Demonstrates oxidative stress and lipid peroxidation from toxic intermediate accumulation in LCHADD RPE cells.
  downstream:
  - target: RPE-specific lipid peroxidation and chorioretinopathy
- name: Cardiolipin remodeling defect and mitochondrial bioenergetic impairment
  description: &#39;The TFP alpha-subunit (HADHA) possesses monolysocardiolipin acyltransferase activity linking fatty acid oxidation
    to cardiolipin remodeling. HADHA mutations disrupt cardiolipin content and composition, leading to reduced mitochondrial
    maximal respiration and spare respiratory capacity. This secondary mitochondrial membrane defect may underlie stress intolerance
    and tissue-specific vulnerability.

    &#39;
  biological_processes:
  - preferred_term: cardiolipin metabolic process
    term:
      id: GO:0046473
      label: cardiolipin metabolic process
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  locations:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  evidence:
  - reference: PMID:39088276
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Although CL reduction was universally identified, a simultaneous increase in monolysocardiolipins was discrepant
      among cells. A similar profile was seen in liver mitochondria isolates from a TFP-deficient mouse model.
    explanation: Demonstrates cardiolipin remodeling defect in TFP/LCHAD-deficient fibroblasts and mouse liver mitochondria.
  - reference: PMID:39088276
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: TFP also catalyzes a step in the remodeling of cardiolipin (CL), a phospholipid critical to mitochondrial membrane
      stability and function.
    explanation: Establishes TFP role in cardiolipin remodeling beyond fatty acid oxidation.
- name: RPE-specific lipid peroxidation and chorioretinopathy
  description: &#39;The retinal pigment epithelium (RPE) relies on fatty acid oxidation for energy, and LCHADD causes a tissue-specific
    block manifesting as progressive chorioretinopathy unique among fatty acid oxidation disorders. RPE cells accumulate 3-hydroxyacylcarnitines
    and are susceptible to DHA-triggered lipid peroxidation, leading to RPE degeneration and vision loss. Exogenous HADHA
    gene addition rescues the biochemical and oxidative stress phenotypes.

    &#39;
  biological_processes:
  - preferred_term: fatty acid beta-oxidation
    term:
      id: GO:0006635
      label: fatty acid beta-oxidation
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  evidence:
  - reference: PMID:39283617
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: LCHADD-RPE express TFP subunits and accumulate 3-hydroxy-acylcarnitines, cannot oxidize palmitate, and release
      fewer ketones than WT-RPE.
    explanation: Demonstrates impaired fatty acid oxidation and metabolite accumulation in LCHADD RPE cells.
  - reference: PMID:38904639
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: LCHADD RPE/sclera samples had a 5- to 7-fold increase in long-chain hydroxyacylcarnitines compared to WT, suggesting
      an impaired LCHAD step in long-chain FAO.
    explanation: Demonstrates tissue-specific accumulation of toxic intermediates in RPE in vivo.
phenotypes:
- name: Hypoketotic hypoglycemia
  frequency: VERY_FREQUENT
  description: &#39;Fasting intolerance with low ketone production and hypoglycemia, reflecting impaired fatty acid oxidation
    and ketogenesis during catabolic states.

    &#39;
  phenotype_term:
    preferred_term: Hypoketotic hypoglycemia
    term:
      id: HP:0001985
      label: Hypoketotic hypoglycemia
  evidence:
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and
      hypocarnitinemia.
    explanation: Directly supports hypoketotic hypoglycemia as a presenting feature of LCHADD.
  - reference: PMID:37644104
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: LCHADD mice exhibit lower ketones with fasting, exhaust earlier during treadmill exercise and develop a dilated
      cardiomyopathy compared to WT mice.
    explanation: Confirms hypoketotic state during fasting in the LCHADD mouse model.
- name: Cardiomyopathy
  frequency: OCCASIONAL
  description: &#39;Cardiac involvement with cardiomyopathy, particularly dilated cardiomyopathy, occurring in approximately 28%
    of screened individuals. Reflects cardiac dependence on fatty acid oxidation for energy.

    &#39;
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  evidence:
  - reference: PMID:38263760
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: neonatal decompensations (28%), symptomatic disease course (94%), later metabolic decompensations (80%), cardiomyopathy
      (28%), myopathy (82%)
    explanation: Quantifies cardiomyopathy at 28% in the German NBS cohort, supporting OCCASIONAL frequency.
  - reference: PMID:37644104
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: LCHADD mice exhibit lower ketones with fasting, exhaust earlier during treadmill exercise and develop a dilated
      cardiomyopathy compared to WT mice.
    explanation: Recapitulates dilated cardiomyopathy in the knock-in mouse model.
- name: Myopathy
  frequency: VERY_FREQUENT
  description: &#39;Skeletal myopathy is the most common long-term complication, occurring in 82% of screened individuals. Manifests
    as exercise intolerance and recurrent rhabdomyolysis triggered by fasting, illness, or exertion.

    &#39;
  phenotype_term:
    preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
  evidence:
  - reference: PMID:38263760
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: neonatal decompensations (28%), symptomatic disease course (94%), later metabolic decompensations (80%), cardiomyopathy
      (28%), myopathy (82%)
    explanation: Quantifies myopathy at 82% in the German NBS cohort, the most frequent complication.
- name: Rhabdomyolysis
  frequency: FREQUENT
  description: &#39;Stress-induced skeletal muscle breakdown with elevated creatine kinase, triggered by fasting, febrile illness,
    or prolonged exercise.

    &#39;
  phenotype_term:
    preferred_term: Rhabdomyolysis
    term:
      id: HP:0003201
      label: Rhabdomyolysis
  evidence:
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other manifestations are cardiomyopathy and rhabdomyolysis, which are frequent in defects of long-chain fatty
      acid oxidation.
    explanation: Confirms rhabdomyolysis as a frequent manifestation in long-chain FAO defects.
  - reference: PMID:32840329
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients may present with rhabdomyolysis induced by exercise; fasting or illness
    explanation: Supports rhabdomyolysis triggered by exercise, fasting, or illness.
- name: Hepatopathy
  frequency: FREQUENT
  description: &#39;Hepatic dysfunction including hepatic steatosis during metabolic decompensation, occurring in approximately
    32% of screened individuals.

    &#39;
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and
      hypocarnitinemia.
    explanation: Confirms hepatic steatosis as a presenting feature.
- name: Chorioretinopathy
  frequency: OCCASIONAL
  description: &#39;Progressive chorioretinopathy unique to LCHADD and not observed in other fatty acid oxidation disorders. Involves
    choroidal atrophy, outer retinal layer disruption, and pigment dispersion. Observed in 17% of screened individuals and
    linked to RPE dysfunction and lipid peroxidation.

    &#39;
  phenotype_term:
    preferred_term: Chorioretinal dystrophy
    term:
      id: HP:0001135
      label: Chorioretinal dystrophy
  evidence:
  - reference: PMID:38595698
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The main ophthalmic symptoms of LCHAD deficiency were choroidal atrophy, disorganization of the outer retinal
      layer, and myopia.
    explanation: Details the specific ophthalmic features of LCHADD chorioretinopathy including choroidal atrophy.
  - reference: PMID:38904639
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: LCHADD mice have progressively decreased visual performance and increased RPE degeneration starting at 6 months.
    explanation: Recapitulates progressive chorioretinopathy in the LCHADD mouse model.
- name: Peripheral neuropathy
  frequency: OCCASIONAL
  description: &#39;Chronic peripheral neuropathy is a recognized long-term complication, occurring in 22% of screened individuals.
    Onset is later in isolated LCHADD (median 11.4 years) compared to combined MTP deficiency (median 3.9 years).

    &#39;
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, LCHAD deficiency has specific features, namely peripheral neuropathy and chorioretinopathy.
    explanation: Confirms peripheral neuropathy as a specific feature of LCHADD.
- name: Metabolic decompensation
  frequency: VERY_FREQUENT
  description: &#39;Recurrent episodes of metabolic decompensation triggered by fasting, febrile illness, or physiologic stress,
    occurring in 80% of screened individuals. Presents with lethargy, vomiting, and hypoglycemia.

    &#39;
  phenotype_term:
    preferred_term: Episodic metabolic acidosis
    term:
      id: HP:0004911
      label: Episodic metabolic acidosis
  evidence:
  - reference: PMID:32840329
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Despite newborn screening, current management options leave many patients continuing to experience major clinical
      events, and mortality rates remain elevated.
    explanation: Supports persistence of metabolic decompensation episodes despite NBS and treatment.
- name: Lethargy
  frequency: FREQUENT
  description: &#39;Decreased alertness and lethargy during episodes of acute metabolic decompensation.

    &#39;
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:10229030
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and
      hypocarnitinemia.
    explanation: Hypoglycemic coma presentation is consistent with severe lethargy during decompensation.
- name: Hypocarnitinemia
  frequency: FREQUENT
  description: &#39;Secondary carnitine deficiency due to increased carnitine conjugation and excretion of accumulated long-chain
    intermediates.

    &#39;
  phenotype_term:
    preferred_term: Decreased circulating carnitine concentration
    term:
      id: HP:0003234
      label: Decreased circulating carnitine concentration
  evidence:
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and
      hypocarnitinemia.
    explanation: Directly supports hypocarnitinemia as a presenting feature of LCHADD.
- name: Exercise intolerance
  frequency: VERY_FREQUENT
  description: &#39;Reduced exercise capacity due to impaired muscle fatty acid oxidation and energy generation.

    &#39;
  phenotype_term:
    preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  evidence:
  - reference: PMID:32840329
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Patients may present with rhabdomyolysis induced by exercise; fasting or illness
    explanation: Supports exercise as a trigger for muscle complications in LC-FAODs including LCHADD, consistent with exercise intolerance.
  - reference: PMID:37644104
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: LCHADD mice exhibit lower ketones with fasting, exhaust earlier during treadmill exercise and develop a dilated
      cardiomyopathy compared to WT mice.
    explanation: Demonstrates exercise intolerance in the LCHADD knock-in mouse model.
- name: Myopia
  frequency: OCCASIONAL
  description: &#39;Progressive shortsightedness observed in LCHADD patients as part of the ophthalmic spectrum.

    &#39;
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
  evidence:
  - reference: PMID:38595698
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The main ophthalmic symptoms of LCHAD deficiency were choroidal atrophy, disorganization of the outer retinal
      layer, and myopia.
    explanation: Confirms myopia as part of the ophthalmic phenotype in LCHADD.
biochemical:
- name: Long-chain 3-hydroxyacylcarnitines (C16OH, C18OH, C18:1OH)
  presence: INCREASED
  context: &#39;Elevated long-chain 3-hydroxyacylcarnitines are the hallmark diagnostic biomarkers for LCHADD, detectable on newborn
    screening by tandem mass spectrometry. These reflect the enzymatic block at the LCHAD step and accumulate in blood, tissues,
    and RPE.

    &#39;
  evidence:
  - reference: PMID:37754774
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The established &#34;HADHA ratio&#34; = (C16OH + C18OH + C18:1OH)/C0 was significantly elevated in all 54 affected individuals
      in comparison to the control group.
    explanation: Quantifies elevation of diagnostic hydroxyacylcarnitines in all affected patients.
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diagnosis is suggested by 3-hydroxylated acylcarnitine species in blood and the definitive diagnosis can be made
      by measuring intermediates of fatty acid beta-oxidation in fibroblasts or by detecting disease causing mutations.
    explanation: Supports 3-hydroxyacylcarnitines as diagnostic biomarkers.
- name: HADHA ratio (C16OH + C18OH + C18:1OH)/C0
  presence: INCREASED
  context: &#39;A novel composite biomarker ratio proposed by Baydakova et al. (2023) that shows high sensitivity and specificity
    for LCHADD/MTP deficiency. The ratio was elevated in all 54 affected individuals tested and was not elevated in VLCAD
    deficiency, providing good differential diagnostic utility.

    &#39;
  evidence:
  - reference: PMID:37754774
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: As VLCAD-deficient patients did not show increased &#34;HADHA ratio&#34;, the results emphasized the high specificity
      of this new ratio.
    explanation: Demonstrates specificity of the HADHA ratio for LCHADD vs VLCAD.
- name: Free carnitine (C0)
  presence: DECREASED
  context: &#39;Secondary carnitine depletion due to increased conjugation and urinary excretion of long-chain acylcarnitines.

    &#39;
  evidence:
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and
      hypocarnitinemia.
    explanation: Directly supports reduced free carnitine in LCHADD.
- name: Ketone bodies
  presence: DECREASED
  context: &#39;Inappropriately low ketone body production during fasting, reflecting impaired hepatic ketogenesis from blocked
    fatty acid oxidation. Also demonstrated in LCHADD RPE cells in vitro.

    &#39;
  evidence:
  - reference: PMID:39283617
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: LCHADD-RPE express TFP subunits and accumulate 3-hydroxy-acylcarnitines, cannot oxidize palmitate, and release
      fewer ketones than WT-RPE.
    explanation: Demonstrates reduced ketone production in LCHADD cells.
  - reference: PMID:37644104
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: LCHADD mice exhibit lower ketones with fasting
    explanation: Confirms hypoketotic phenotype in the LCHADD mouse model.
- name: Cardiolipin
  presence: DECREASED
  context: &#39;Cardiolipin reduction in mitochondrial membranes, with concurrent increase in monolysocardiolipins, reflecting
    impaired cardiolipin remodeling by the TFP alpha-subunit.

    &#39;
  evidence:
  - reference: PMID:39088276
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Although CL reduction was universally identified, a simultaneous increase in monolysocardiolipins was discrepant
      among cells. A similar profile was seen in liver mitochondria isolates from a TFP-deficient mouse model.
    explanation: Demonstrates universal cardiolipin reduction in TFP-deficient cells and mouse liver.
genetic:
- name: HADHA pathogenic variants causing LCHADD
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:10229030
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In the vast majority of patients, LCHAD deficiency is caused by a common autosomal recessive mutation G1528C.
      explanation: Directly supports autosomal recessive inheritance pattern.
  variants:
  - name: HADHA c.1528G&gt;C (p.Glu510Gln)
    description: &#39;The most common pathogenic variant in LCHADD, a founder mutation affecting the LCHAD catalytic site. This
      variant selectively impairs LCHAD activity while relatively preserving the other two TFP enzymatic functions (enoyl-CoA
      hydratase and 3-ketoacyl-CoA thiolase). Carrier frequency in Finland is 1:240.

      &#39;
    evidence:
    - reference: PMID:10229030
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In the vast majority of patients, LCHAD deficiency is caused by a common autosomal recessive mutation G1528C.
      explanation: Confirms c.1528G&gt;C as the predominant mutation.
    - reference: PMID:10229030
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Analysis of the frequency of the G1528C mutation in Finland revealed carrier frequency of 1:240.
      explanation: Quantifies carrier frequency in the Finnish population.
  features: &#39;LCHADD is caused by biallelic pathogenic variants in HADHA, which encodes the alpha-subunit of the mitochondrial
    trifunctional protein. The common c.1528G&gt;C (p.Glu510Gln) founder mutation selectively reduces LCHAD catalytic activity.
    Other HADHA or HADHB variants that reduce multiple TFP enzyme activities cause the broader phenotype of mitochondrial
    trifunctional protein deficiency (MTPD), which has a similar but often more severe clinical course including earlier neuropathy
    onset.

    &#39;
  evidence:
  - reference: PMID:38263760
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Disease courses in screened individuals with LCHAD and MTP deficiency were similar except for neuropathy, occurring
      earlier in individuals with MTP deficiency (median 3.9 vs. 11.4 years; p = 0.0447).
    explanation: Distinguishes LCHADD from MTPD clinical course.
  - reference: PMID:39088276
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: A single common mutation, HADHA c.1528G&gt;C (p.E510Q), leads to isolated 3-hydroxyacyl-CoA dehydrogenase deficiency.
    explanation: Distinguishes isolated LCHAD from combined TFP deficiency at the genetic level.
treatments:
- name: Dietary fat restriction with MCT supplementation
  description: &#39;Core dietary management involves restriction of long-chain triglycerides (LCT) to approximately 10% of total
    energy with supplementation of medium-chain triglycerides (MCT) at 10-25% of total energy. Essential fatty acid intake
    (linoleic and linolenic acid) must be maintained. Avoidance of prolonged fasting is critical.

    &#39;
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:39203843
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In long-chain deficits, long-chain triglyceride restriction should be 10% of total energy, with linoleic acid
      and linolenic acid intake of 3-4% and 0.5-1% (5/1-10/1 ratio), with medium-chain triglyceride supplementation at 10-25%
      of total energy
    explanation: Specifies LCT restriction and MCT supplementation targets for long-chain FAO defects.
  - reference: PMID:39203843
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment of fatty acid oxidation disorders is based on dietary, pharmacological and metabolic decompensation
      measures. It is essential to provide the patient with sufficient glucose to prevent lipolysis and to avoid the use of
      fatty acids as fuel as far as possible.
    explanation: Supports dietary management as the foundation of FAOD treatment.
- name: Emergency glucose infusion for acute decompensation
  description: &#39;Acute metabolic decompensation requires emergency IV glucose administration (10% dextrose at approximately
    8 mg/kg/min) to suppress lipolysis and catabolism. Cessation of protein and fat intake and monitoring of electrolytes
    and creatine kinase are essential.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:32840329
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Long-chain fatty acid oxidation disorders (LC-FAODs) are rare, life-threatening, autosomal recessive genetic
      disorders characterized by acute crises of energy production and chronic energy deficiency.
    explanation: Supports the need for emergency management of acute metabolic crises.
  - reference: PMID:39203843
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The main measure in emergency hospital treatment is the administration of IV glucose.
    explanation: Directly supports IV glucose as the primary emergency intervention.
- name: Triheptanoin (Dojolvi)
  description: &#39;Triheptanoin is an FDA-approved odd-chain triglyceride providing anaplerotic substrate (propionyl-CoA converted
    to succinyl-CoA) to support TCA cycle intermediate replenishment and energy generation in long-chain fatty acid oxidation
    disorders. Reported to reduce decompensation frequency and hospitalizations.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:32840329
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In recent years, the use of medium, odd-chain fatty acids, such as triheptanoin, have been studied as a treatment
      of LC-FAODs due to its anaplerotic properties.
    explanation: Supports triheptanoin as an anaplerotic therapy for LC-FAODs.
  - reference: PMID:39203843
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Trihepatnoin is a new therapeutic option with a good safety and efficacy profile.
    explanation: Confirms triheptanoin as a therapeutic option with favorable profile. Note &#34;Trihepatnoin&#34; is a typo in the original publication abstract.
- name: Newborn screening
  description: &#39;Expanded newborn screening using tandem mass spectrometry acylcarnitine profiling identifies affected infants
    presymptomatically. Screening detects elevated C16OH, C18OH, and C18:1OH. While NBS improves neonatal survival, it does
    not reliably prevent long-term morbidity.

    &#39;
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:38263760
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Sixty-seven individuals with LCHAD/MTP deficiency were included in the study, thereof 54 identified by NBS. All
      screened individuals with LCHAD deficiency survived
    explanation: Demonstrates improved survival with NBS but persistent morbidity.
  - reference: PMID:37754774
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The established &#34;HADHA ratio&#34; = (C16OH + C18OH + C18:1OH)/C0 was significantly elevated in all 54 affected individuals
      in comparison to the control group.
    explanation: Supports acylcarnitine-based NBS biomarkers for LCHADD detection.
- name: Carnitine supplementation
  description: &#39;L-carnitine supplementation to address secondary carnitine deficiency and support excretion of toxic acyl-CoA
    intermediates as acylcarnitines. Use remains somewhat controversial but commonly employed.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:39203843
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The use of carnitine remains controversial and new therapeutic options are under investigation.
    explanation: Acknowledges carnitine supplementation while noting it remains controversial.
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Like several beta-oxidation defects, it presents during infancy with hypoglycemic coma, hepatic steatosis, and
      hypocarnitinemia.
    explanation: Supports the rationale for carnitine supplementation given hypocarnitinemia.
- name: Ophthalmologic monitoring
  description: &#39;Regular retinal screening for chorioretinopathy is essential for all LCHADD patients, as choroidal atrophy
    and pigment dispersion are early signs of retinal degeneration. European metabolic centers concur on the importance of
    retinopathy screening as part of long-term monitoring.

    &#39;
  treatment_term:
    preferred_term: eye examination
    term:
      id: MAXO:0001155
      label: eye examination
  evidence:
  - reference: PMID:38245779
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The centres concurred in many aspects of long-term monitoring of LCFAOD including the frequency of clinical visits,
      determination of laboratory parameters, cardiac monitoring and retinopathy screening.
    explanation: Confirms retinopathy screening as a consensus monitoring practice.
  - reference: PMID:38595698
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Choroidal atrophy and pigment dispersion were consistently the earliest signs of LCHAD-associated chorioretinopathy.
    explanation: Supports the importance of regular ophthalmologic monitoring to detect early signs.
- name: Genetic counseling
  description: &#39;Genetic counseling for affected families including discussion of autosomal recessive inheritance, recurrence
    risk (25% for carrier parents), carrier testing, and prenatal diagnostic opportunities.

    &#39;
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:10229030
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Because of therapeutic and prenatal diagnostic opportunities in LCHAD deficiency, it is important to recognize
      this severe disorder early in its course.
    explanation: Supports the importance of early diagnosis and prenatal counseling for LCHADD.
- name: Cardiac monitoring and management
  description: &#39;Regular cardiac monitoring with echocardiography is recommended given the 28% prevalence of cardiomyopathy.
    European metabolic centers include cardiac monitoring as a consensus practice in long-term follow-up of LCFAOD patients.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:38245779
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The centres concurred in many aspects of long-term monitoring of LCFAOD including the frequency of clinical visits,
      determination of laboratory parameters, cardiac monitoring and retinopathy screening.
    explanation: Confirms cardiac monitoring as consensus practice in European metabolic centers.
environmental:
- name: Fasting and catabolic stress
  description: &#39;Prolonged fasting, febrile illness, and physiologic stress increase reliance on fatty acid oxidation and trigger
    metabolic decompensation. Fasting avoidance is the cornerstone of preventive management.

    &#39;
  evidence:
  - reference: PMID:32840329
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients may present with rhabdomyolysis induced by exercise; fasting or illness; hepatic dysfunction, including
      severe hypoglycemia and hyperammonemia; and cardiomyopathy.
    explanation: Identifies fasting, exercise, and illness as triggers for clinical manifestations.
notes: &#39;LCHADD is distinguished from the broader mitochondrial trifunctional protein deficiency (MTPD) by the selective impairment
  of LCHAD activity due to the common HADHA c.1528G&gt;C variant. MTPD involves additional loss of enoyl-CoA hydratase and 3-ketoacyl-CoA
  thiolase activities due to other HADHA or HADHB variants. An association between fetal LCHAD/MTP deficiency and maternal
  acute fatty liver of pregnancy (AFLP) or HELLP syndrome has been described, attributed to toxic 3-hydroxy intermediate metabolites
  released from the deficient placenta into maternal circulation. Emerging 2024 research demonstrates a gene therapy approach
  using AAV-HADHA to rescue RPE cell phenotypes, providing preclinical rationale for retinal gene-addition therapy.

  &#39;
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Long-Chain_3-Hydroxyacyl-CoA_Dehydrogenase_Deficiency.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>